Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
Pituitary neuroendocrine tumors (PitNET) are commonly benign tumors accounting for 10-25% of intracranial tumors. Prolactin-secreting adenomas represent the most predominant type of all PitNET and for this subtype of tumors, the medical therapy relies on the use of dopamine agonists (DAs). DAs yield...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.791633/full |
| _version_ | 1798020979545341952 |
|---|---|
| author | Claudia Pivonello Roberta Patalano Roberta Patalano Mariarosaria Negri Rosa Pirchio Annamaria Colao Annamaria Colao Rosario Pivonello Rosario Pivonello Renata Simona Auriemma |
| author_facet | Claudia Pivonello Roberta Patalano Roberta Patalano Mariarosaria Negri Rosa Pirchio Annamaria Colao Annamaria Colao Rosario Pivonello Rosario Pivonello Renata Simona Auriemma |
| author_sort | Claudia Pivonello |
| collection | DOAJ |
| description | Pituitary neuroendocrine tumors (PitNET) are commonly benign tumors accounting for 10-25% of intracranial tumors. Prolactin-secreting adenomas represent the most predominant type of all PitNET and for this subtype of tumors, the medical therapy relies on the use of dopamine agonists (DAs). DAs yield an excellent therapeutic response in reducing tumor size and hormonal secretion targeting the dopamine receptor type 2 (D2DR) whose higher expression in prolactin-secreting adenomas compared to other PitNET is now well established. Moreover, although DAs therapy does not represent the first-line therapy for other PitNET, off-label use of DAs is considered in PitNET expressing D2DR. Nevertheless, DAs primary or secondary resistance, occurring in a subset of patients, may involve several molecular mechanisms, presently not fully elucidated. Dopamine receptors (DRs) expression is a prerequisite for a proper DA function in PitNET and several molecular events may negatively modify DR membrane expression, through the DRs down-regulation and intracellular trafficking, and DR signal transduction pathway. The current mini-review will summarise the presently known molecular events that underpin the unsuccessful therapy with DAs. |
| first_indexed | 2024-04-11T17:06:31Z |
| format | Article |
| id | doaj.art-0060cc39bf7a4b08bb259814b161fbc6 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-11T17:06:31Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-0060cc39bf7a4b08bb259814b161fbc62022-12-22T04:13:01ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-01-011210.3389/fendo.2021.791633791633Resistance to Dopamine Agonists in Pituitary Tumors: Molecular MechanismsClaudia Pivonello0Roberta Patalano1Roberta Patalano2Mariarosaria Negri3Rosa Pirchio4Annamaria Colao5Annamaria Colao6Rosario Pivonello7Rosario Pivonello8Renata Simona Auriemma9Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università di Napoli (Federico II), Naples, ItalyDipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università di Napoli (Federico II), Naples, ItalyDipartimento di Sanità Pubblica, Università di Napoli (Federico II), Naples, ItalyDipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università di Napoli (Federico II), Naples, ItalyDipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università di Napoli (Federico II), Naples, ItalyDipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università di Napoli (Federico II), Naples, ItalyUnited Nations Educational, Scientific and Cultural Organization (UNESCO) Chair for Health Education and Sustainable Development, Federico II University, Naples, ItalyDipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università di Napoli (Federico II), Naples, ItalyUnited Nations Educational, Scientific and Cultural Organization (UNESCO) Chair for Health Education and Sustainable Development, Federico II University, Naples, ItalyDipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università di Napoli (Federico II), Naples, ItalyPituitary neuroendocrine tumors (PitNET) are commonly benign tumors accounting for 10-25% of intracranial tumors. Prolactin-secreting adenomas represent the most predominant type of all PitNET and for this subtype of tumors, the medical therapy relies on the use of dopamine agonists (DAs). DAs yield an excellent therapeutic response in reducing tumor size and hormonal secretion targeting the dopamine receptor type 2 (D2DR) whose higher expression in prolactin-secreting adenomas compared to other PitNET is now well established. Moreover, although DAs therapy does not represent the first-line therapy for other PitNET, off-label use of DAs is considered in PitNET expressing D2DR. Nevertheless, DAs primary or secondary resistance, occurring in a subset of patients, may involve several molecular mechanisms, presently not fully elucidated. Dopamine receptors (DRs) expression is a prerequisite for a proper DA function in PitNET and several molecular events may negatively modify DR membrane expression, through the DRs down-regulation and intracellular trafficking, and DR signal transduction pathway. The current mini-review will summarise the presently known molecular events that underpin the unsuccessful therapy with DAs.https://www.frontiersin.org/articles/10.3389/fendo.2021.791633/fulldopaminedopamine agonistpituitary tumorscabergolineprolactinomas |
| spellingShingle | Claudia Pivonello Roberta Patalano Roberta Patalano Mariarosaria Negri Rosa Pirchio Annamaria Colao Annamaria Colao Rosario Pivonello Rosario Pivonello Renata Simona Auriemma Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms Frontiers in Endocrinology dopamine dopamine agonist pituitary tumors cabergoline prolactinomas |
| title | Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms |
| title_full | Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms |
| title_fullStr | Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms |
| title_full_unstemmed | Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms |
| title_short | Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms |
| title_sort | resistance to dopamine agonists in pituitary tumors molecular mechanisms |
| topic | dopamine dopamine agonist pituitary tumors cabergoline prolactinomas |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2021.791633/full |
| work_keys_str_mv | AT claudiapivonello resistancetodopamineagonistsinpituitarytumorsmolecularmechanisms AT robertapatalano resistancetodopamineagonistsinpituitarytumorsmolecularmechanisms AT robertapatalano resistancetodopamineagonistsinpituitarytumorsmolecularmechanisms AT mariarosarianegri resistancetodopamineagonistsinpituitarytumorsmolecularmechanisms AT rosapirchio resistancetodopamineagonistsinpituitarytumorsmolecularmechanisms AT annamariacolao resistancetodopamineagonistsinpituitarytumorsmolecularmechanisms AT annamariacolao resistancetodopamineagonistsinpituitarytumorsmolecularmechanisms AT rosariopivonello resistancetodopamineagonistsinpituitarytumorsmolecularmechanisms AT rosariopivonello resistancetodopamineagonistsinpituitarytumorsmolecularmechanisms AT renatasimonaauriemma resistancetodopamineagonistsinpituitarytumorsmolecularmechanisms |